1979
DOI: 10.1016/0016-5085(79)90386-x
|View full text |Cite
|
Sign up to set email alerts
|

National Cooperative Crohn's Disease Study: Adverse reactions to study drugs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
67
0
4

Year Published

2007
2007
2015
2015

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 237 publications
(72 citation statements)
references
References 32 publications
1
67
0
4
Order By: Relevance
“…1 Surgery is among the most important concerns of patients affected by CD. In fact, concerns about having surgery and having an ostomy bag have a significant impact on health-related quality of life (HRQL) of CD patients, and having surgery increases concerns about body stigma.…”
Section: Introductionmentioning
confidence: 99%
“…1 Surgery is among the most important concerns of patients affected by CD. In fact, concerns about having surgery and having an ostomy bag have a significant impact on health-related quality of life (HRQL) of CD patients, and having surgery increases concerns about body stigma.…”
Section: Introductionmentioning
confidence: 99%
“…Systemic GCSs, such as prednisolone, are effective in high doses for treatment of active disease in patients with CD, 20, 21 but they are frequently associated with clinically important steroid-related AEs. 4 Low doses of systemic GCSs, on the other hand, do not appear to be effective for prolongation of remission. 20,22 Current therapies for maintenance treatment of mild-to-moderate CD are either viewed as safe but of uncertain efficacy or effective but of limited use because of SAEs.…”
Section: Discussionmentioning
confidence: 96%
“…1 Systemic glucocorticosteroids (GCSs), such as prednisone or prednisolone, are an effective treatment for CD; however, they are associated with clinically important adverse events (AEs), such as adrenal suppression, hypertension, impaired glucose tolerance, cataracts, osteoporosis, osteonecrosis, psychiatric disorders and other cushingoid symptoms. [2][3][4] Thus, although systemic GCSs are efficacious for the treatment of active CD, they are not recommended for long-term treatment of CD.…”
Section: Introductionmentioning
confidence: 96%
“…Controlled studies show that patients with mildly and moderately active CD may respond to corticosteroids [1]. However, corticosteroid treatment cannot be used over a long period without the risk of various steroid-related adverse effects [2]. Nonsteroidal drugs like 5-aminosalicylic acid (5-ASA), azathioprine, 6-mercaptoprine, and infliximab are additional medications for inducing remission [3].…”
Section: Introductionmentioning
confidence: 99%